Relmada Therapeutics (RLMD) Preferred Shares (2014 - 2015)
Relmada Therapeutics (RLMD) reported Preferred Shares of $72.0 for Q3 2015, down 97.84% year-over-year from $3337.0 in Q3 2014, and little changed on a QoQ basis from $72.0 in Q2 2015.
Relmada Therapeutics (RLMD) has 2 years of Preferred Shares data on file, last reported at $72.0 in Q3 2015.
- Quarterly Preferred Shares fell 97.84% year-over-year to $72.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $72.0 (down 97.84% YoY) and the FY2015 annual result came in at $72.0, down 89.21% from the prior year.
- Preferred Shares was little changed at $72.0 in Q3 2015 per RLMD's latest filing, from $72.0 in the prior quarter.
- Across five years, Preferred Shares topped out at $3337.0 in Q3 2014 and bottomed at $72.0 in Q2 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 72.00 |
| Jun 30, 2015 | 72.00 |
| Mar 31, 2015 | 465.00 |
| Dec 31, 2014 | 465.00 |
| Sep 30, 2014 | 3,337.00 |
| Jun 30, 2014 | 667.00 |